Moomoo AI 已提取核心信息
On December 31, 2023, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 9.99% ownership stake in Adial Pharmaceuticals, Inc. This stake amounts to 166,972 shares in the company's common stock. The filing indicates that Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the securities held by the Master Fund. Consequently, both Armistice Capital and Steven Boyd may be deemed to beneficially own the securities of Adial Pharmaceuticals held by the Master Fund. The Master Fund, however, disclaims beneficial ownership of these securities due to its Investment Management Agreement with Armistice Capital, which limits its ability to vote or dispose...Show More
On December 31, 2023, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 9.99% ownership stake in Adial Pharmaceuticals, Inc. This stake amounts to 166,972 shares in the company's common stock. The filing indicates that Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the securities held by the Master Fund. Consequently, both Armistice Capital and Steven Boyd may be deemed to beneficially own the securities of Adial Pharmaceuticals held by the Master Fund. The Master Fund, however, disclaims beneficial ownership of these securities due to its Investment Management Agreement with Armistice Capital, which limits its ability to vote or dispose of the securities. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, which applies to certain investment advisers and parent holding companies. The report emphasizes that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Adial Pharmaceuticals.
2023年12月31日，停战资本有限责任公司及其管理成员史蒂芬·博伊德向美国证券交易委员会提交了附表13G，披露了阿迪尔制药公司9.99％的所有权，该股份相当于该公司普通股的166,972股。该文件显示，作为停战资本主基金有限公司的投资经理，停战资本对主基金持有的证券行使投票权和投资权。因此，停战资本和史蒂芬·博伊德都可能被视为受益拥有主基金持有的Adial Pharmicals的证券。但是，主基金宣布放弃对这些证券的实益所有权，因为其与Armistice Capital签订了投资管理协议，这限制了其投票或处置证券的能力。该文件是根据1934年《证券交易法》第13d-1（b）条提交的，该规则适用于某些投资顾问和母控股公司。该报告强调，这些股票是在正常业务过程中收购的，不是为了改变或影响Adial Pharmicals的控制权。
2023年12月31日，停战资本有限责任公司及其管理成员史蒂芬·博伊德向美国证券交易委员会提交了附表13G，披露了阿迪尔制药公司9.99％的所有权，该股份相当于该公司普通股的166,972股。该文件显示，作为停战资本主基金有限公司的投资经理，停战资本对主基金持有的证券行使投票权和投资权。因此，停战资本和史蒂芬·博伊德都可能被视为受益拥有主基金持有的Adial Pharmicals的证券。但是，主基金宣布放弃对这些证券的实益所有权，因为其与Armistice Capital签订了投资管理协议，这限制了其投票或处置证券的能力。该文件是根据1934年《证券交易法》第13d-1（b）条提交的，该规则适用于某些投资顾问和母控股公司。该报告强调，这些股票是在正常业务过程中收购的，不是为了改变或影响Adial Pharmicals的控制权。
有用
没用
